Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 22 |
| Active Pipeline (Recruiting Now) | 9 (5) |
| Completed vs Stopped Early | 10 / 3 (13.6%) |
| Median Closed Actual Enrollment | 181 participants |
| Physical Hospital Site Disclosure | 99.7% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Hospital Universitari Vall d'Hebron | Barcelona | 7 |
| Yale Cancer Center and Smilow Cancer Hospital | New Haven, CT | 4 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT04965675 | A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine | Phase III | RECRUITING |
| NCT05164172 | A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine | Phase III | RECRUITING |
| NCT05897320 | A Study of Eptinezumab in Pediatric Participants With Episodic Migraine | Phase III | RECRUITING |
| NCT05104476 | A Study of Lu AF82422 in Participants With Multiple System Atrophy | Phase II | ACTIVE NOT RECRUITING |
| NCT06471829 | A Trial of Lu AG13909 in Adult Participants With Cushing's Disease | Phase II | ACTIVE NOT RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the H. Lundbeck Interactive Dossier, benchmark peers in Neurology, Psychiatry, and Pain, or review the Healthcare Price & Patent Cliff Crosswalk.